Tesamorelin 30mg — Vial Spec, Reconstitution Math & COA

Tesamorelin 30mg Overview & Catalog Specifications

Tesamorelin is a trans-3-hexenoic acid-modified synthetic peptide comprising 44 amino acids. In preclinical research, it functions as a stable growth hormone secretagogue by binding directly to human GHRH receptors on pituitary somatotropes. The 30mg vial configuration represents a concentrated bulk-assay format tailored for institutional laboratories conducting high-volume binding affinity studies, cell culture exposures, or longitudinal animal model evaluations.

Please note: PX1 Research standardly stocks and distributes high-purity Tesamorelin 10mg vials to ensure maximum stability and minimize freeze-thaw degradation cycles for standard laboratory protocols. However, for specialized research groups requiring 30mg mass metrics, understanding the volumetric reconstitution mathematics, concentration curves, and analytical parameters remains essential. Researchers can review our complete inventory of analytical-grade compounds across our all peptides catalog.

Molecular Structure and Preclinical Mechanism of Action

The molecular structure of Tesamorelin ($C_{221}H_{366}N_{72}O_{67}S$) incorporates a hexenoyl moiety attached to the N-terminal residue of human GHRH(1-44). In vitro assay models demonstrate that this structural modification enhances enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV) cleavage compared to native GHRH, extending its biological half-life in culture media and plasma buffers.

Preclinical studies suggest that Tesamorelin selectively activates the GHRH receptor, initiating intracellular cyclic adenosine monophosphate (cAMP) signaling cascades. This mechanism stimulates the endogenous release of growth hormone (GH), which subsequently upregulates insulin-like growth factor 1 (IGF-1) synthesis in hepatic cell models. Researchers investigate these pathways to explore downstream signaling in lipid oxidation, visceral adipose tissue metabolism, cardiac extracellular matrix remodeling, and peripheral nerve regeneration.

Reconstitution Mathematics for 30mg Mass Configurations

Reconstituting a high-mass lyophilized cake like Tesamorelin 30mg requires careful volumetric calculations to achieve intended working concentrations ($μg/μL$ or $mg/mL$). Because a 30mg payload presents a larger solute volume, researchers must factor in displacement and ensure complete dissolution using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile physiological saline.

To calculate working stock concentration ($C$), use the formula $C = \frac{m}{V}$, where $m$ is the peptide mass (30 mg) and $V$ is the diluent volume in milliliters:

• 1.0 mL Diluent Volume: Reconstitution with 1.0 mL yields a highly concentrated working stock of $30.0\text{ mg/mL}$ ($30.0\text{ }\mu\text{g/}\mu\text{L}$). This ultra-high concentration is typically utilized for automated micro-dispensing systems or high-density aliquot arrays.

• 2.0 mL Diluent Volume: Reconstitution with 2.0 mL yields a stock concentration of $15.0\text{ mg/mL}$ ($15.0\text{ }\mu\text{g/}\mu\text{L}$). This mid-range ratio facilitates precise pipetting for cellular incubation assays while maintaining liquid stability.

• 3.0 mL Diluent Volume: Reconstitution with 3.0 mL yields a working concentration of $10.0\text{ mg/mL}$ ($10.0\text{ }\mu\text{g/}\mu\text{L}$). This standard concentration provides straightforward volumetric partitioning for preclinical animal model research.

For complex dilutions or multi-vial master mix calculations, laboratory technicians should consult our interactive reconstitution calculator to ensure absolute precision prior to liquid handling.

Aliquot Planning and Volumetric Handling Protocols

When handling a reconstituted 30mg Tesamorelin vial, repeated freeze-thaw cycles must be strictly avoided to prevent peptide aggregation and peptide chain cleavage. High-yield vials are best partitioned immediately following complete dissolution into single-use micro-aliquots within sterile polypropylene microcentrifuge tubes.

For example, a 30mg vial reconstituted in 3.0 mL of diluent ($10\text{ mg/mL}$) can be split into thirty $100\text{ }\mu\text{L}$ aliquots (containing $1.0\text{ mg}$ per tube) or sixty $50\text{ }\mu\text{L}$ aliquots (containing $500\text{ }\mu\text{g}$ per tube). Each aliquot should be snap-frozen in liquid nitrogen or an ultra-low temperature freezer ($-80^\circ\text{C}$) to preserve structural integrity over extended study timelines. When preparing working solutions for cell culture, ensure diluent compatibility to prevent osmotic shock in in vitro assays.

Analytical Certificate of Analysis (COA) Verification

Every production lot of research peptides distributed by PX1 Research undergoes stringent third-party verification within an ISO 17025 accredited laboratory. Our analytical verification process guarantees that each lot meets exact structural and purity criteria before release to the scientific community.

To verify lot purity, samples are subjected to High-Performance Liquid Chromatography (HPLC), establishing a purity threshold exceeding 99.0%. Mass Spectrometry (MS) is simultaneously performed to confirm the exact molecular mass ($4496.05\text{ Da}$) against theoretical standards. Furthermore, every batch undergoes chromogenic Limulus Amebocyte Lysate (LAL) assay testing to verify that bacterial endotoxin levels remain strictly below $<0.01\text{ EU/mg}$. Laboratory directors can examine lot-matched documentation directly on our dedicated COA verification hub.

Comparative Analysis: GHRH and Secretagogue Research Class

When designing protocols around the growth hormone axis, investigators frequently evaluate multiple GHRH analogs and growth hormone secretagogues to compare receptor kinetics, half-life, and biological signaling profiles. Tesamorelin is unique due to its N-terminal trans-3-hexenoic acid modification, which provides distinct binding characteristics compared to other peptides in its class.

In comparative preclinical literature, Tesamorelin is routinely evaluated alongside CJC-1295 DAC, which features a bioconjugate affinity complex extending plasma retention, and Sermorelin, an truncated 29-amino-acid GHRH fragment ($GHRH_{1-29}$). Researchers also pair GHRH analogs with ghrelin receptor agonists like Ipamorelin to study synergistic GH release profiles in somatotrope cell cultures. Understanding these structural variations allows laboratories to select the exact molecular candidate required for their specific experimental design.

10mg vs. 30mg Format Selection Guidelines for Research Labs

Selecting between a 30mg bulk format and smaller vial sizes—such as the standard Tesamorelin 10mg format—depends entirely on assay throughput, project timeline, and reconstitution volume constraints. While a 30mg vial offers higher mass per container, it demands precise cold-chain management and rapid utilization upon reconstitution to avoid liquid-phase degradation.

For bench-scale pilot studies, transient cell culture assays, or small-cohort rodent research, smaller 10mg vials are generally preferred. They minimize open-container exposure, reduce the risk of accidental hydrolysis during pipetting, and prevent unnecessary loss of compound. Conversely, automated high-throughput screening platforms and large-scale comparative trial facilities benefit from bulk mass units. Institutional purchasing departments managing large-scale compound requisitions can explore our institutional access programs through the PX1 wholesale portal.

Storage Parameters and Degradation Dynamics

Lyophilized Tesamorelin is exceptionally stable when stored under climate-controlled conditions. Prior to reconstitution, unopened 30mg vials should be maintained at $-20^\circ\text{C}$ to $4^\circ\text{C}$ in a desiccated environment, shielded from light exposure. Under these parameters, the lyophilized peptide maintains structural stability for extended periods without significant degradation.

Once reconstituted with bacteriostatic diluent, the solution must be stored strictly at $2^\circ\text{C}$ to $8^\circ\text{C}$ and utilized within 28 days. In vitro research demonstrates that aqueous peptide solutions are subject to oxidation and deamidation over time, particularly when exposed to ambient temperatures or excessive agitation. Solutions reconstituted with non-preserved sterile water must be used immediately or micro-aliquoted and frozen to maintain analytical consistency across experimental replicate groups. Detailed research guidelines on peptide stability are hosted within our research library hub.